Podcasts Health Empowered Patient Podcast Immunotherapies Using Fully Human Polyclonal Antibodies Without Need for Convalescent Plasma Blood Donors with Eddie Sullivan SAb Biotherapeutics

Immunotherapies Using Fully Human Polyclonal Antibodies Without Need for Convalescent Plasma Blood Donors with Eddie Sullivan SAb Biotherapeutics

Published: June 10, 2020, 4:16 p.m.

Eddie Sullivan, President, CEO, Co-Founder, SAb Biotherapeutics talks about their innovative technology to generate targeted highly potent immunotherapies on a large scale.  SAb is producing fully human polyclonal antibodies targeted to COVID-19 without the need for convalescent plasma blood donations by using genetically engineered cattle which produce the fully human antibodies.

@SABBantibody 

#COVID19 #immunotherapies #antibodies

SAbbiotherapeutics.com/covid-19

Download the transcript here

SAb